Turnstone Biologics Corporation (TSBX) News

Form 8-K - Current report

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]

Form S-8 - Securities to be offered to employees in employee benefit plans

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Turnstone Biologics Corp. Reports First Quarter 2024 Financial Results and Provides Recent Business Highlights

SAN DIEGO, May 13, 2024 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. (“Turnstone” or the “Company”) (Nasdaq:...

Turnstone Biologics to Present at the 2024 Bank of America Securities Health Care Conference

SAN DIEGO, May 08, 2024 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. (“Turnstone” or the “Company”) (Nasdaq:...

Turnstone Biologics Appoints William Waddill to its Board of Directors

SAN DIEGO, April 16, 2024 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. (“Turnstone” or the “Company”...

Turnstone Biologics Corp. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Recent Business Highlights

Lead program, TIDAL-01, advancing in Phase 1 trials with initial clinical data expected in mid-2024 Promising...

Form 8-K - Current report

Turnstone Biologics to Participate in Upcoming Investor Conferences

SAN DIEGO, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. (“Turnstone” or the “Company”...

Turnstone Biologics Announces the Passing of Chief Legal Officer P. Joseph Campisi, Jr., Esq.

SAN DIEGO, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. (“Turnstone” or the “Company”...

Turnstone Biologics to Participate in the Piper Sandler 35th Annual Healthcare Conference

SAN DIEGO, Nov. 27, 2023 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. (“Turnstone”) (Nasdaq: TSBX), a...

Turnstone Biologics Corp. Reports Third Quarter 2023 Financial Results and Provides Recent Business Highlights

– Promising preclinical data showcasing Turnstone’s novel Selected TIL programs for solid tumors presented at...

Turnstone Biologics Presents Preclinical Data Highlighting Potential for Selected Tumor-Infiltrating Lymphocyte (TIL) Therapy in Solid Tumors at the 2023 Society for Immunotherapy of Cancer (SITC) Annual Meeting

Presentations showcase Turnstone’s novel Selected TIL programs which are designed to selectively expand the...